Holen Sie sich die Stockscreener-App
3.12
5.17%
-0.17
Schlusskurs vom Vortag:
$3.29
Offen:
$3.25
24-Stunden-Volumen:
152.37K
Relative Volume:
0.64
Marktkapitalisierung:
$18.38M
Einnahmen:
$14.58M
Nettoeinkommen (Verlust:
$-12.57M
KGV:
-0.5493
EPS:
-5.68
Netto-Cashflow:
$-13.07M
1W Leistung:
-22.00%
1M Leistung:
-44.39%
6M Leistung:
+9.98%
1J Leistung:
-36.71%
1-Tages-Spanne:
$3.01
$3.325
1-Wochen-Bereich:
$3.01
$4.27
52-Wochen-Spanne:
$1.91
$6.28
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Firmenname
Vivos Therapeutics Inc
Sektor
Branche
Telefon
(866)908-4867
Adresse
7921 SOUTHPARK PLAZA,, LITTLETON
Vergleichen Sie VVOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
3.12 | 18.38M | 14.58M | -12.57M | -13.07M | -5.68 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Vivos Therapeutics Inc Aktie (VVOS) Neueste Nachrichten
Reviewing Vivos Therapeutics (NASDAQ:VVOS) & Biostage (OTCMKTS:BSTG) - Defense World
Vivos Therapeutics Inc to Host Earnings Call - ACCESS Newswire
Vivos Therapeutics to participate in Fireside Chat with Water Tower Research - Proactive Investors UK
Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12:00 pm - EIN News
Investors Give Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares A 30% Hiding - Simply Wall St
Vivos Therapeutics Enters Into At The Market Offering Agreement with H.C. Wainwright & Co., LLC**Littleton, Colo. – Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced on February 14, 2025, that the company has entered into an At The Market Offering - Defense World
Vivos Therapeutics Enters Market Offering Agreement with Wainwright - TipRanks
Vivos Therapeutics announces up to $50M mixed shelf offering - MSN
Vivos Therapeutics Inc Files For Mixed Shelf Of Up To $50 MillionSEC Filing -February 11, 2025 at 05:44 pm EST - Marketscreener.com
Trapped in CPAP Dependency? Vivos Liberates OSA Patients with Non-Invasive Solution - PR Web
Vivos Therapeutics announces sale of up to 854,332 shares by selling stockholders - MSN
Vivos Therapeutics (VVOS) Stock Price, News & Analysis - MarketBeat
VVOS Stock Price and Chart — NASDAQ:VVOS — TradingView«Кавказ Пост» - «Кавказ Пост» - новости Северного Кавказа и Закавказья
Best Momentum Stocks to Buy for January 8th - MSN
Recognizing Sleep as the Sixth Vital Sign: How Vivos Is Redefining Health Care - PR Web
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 28.9% in December - Defense World
After Leaping 35% Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares Are Not Flying Under The Radar - Simply Wall St
Vivos Therapeutics announces $3.5 million stock offering - Investing.com
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Vivos Therapeutics Secures $3.5M Financing Through Strategic Share Offering and Warrants - StockTitan
Vivos Therapeutics announces funding boost - Proactive Investors USA
Vivos Therapeutics (NASDAQ:VVOS) Stock Price Up 6.9% – What’s Next? - Defense World
All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy - Yahoo Finance
FDA-Cleared Therapy for Pediatric Sleep Apnea From Vivos Offers Parents and Providers New Hope - PR Web
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Water Tower Research Publishes Initiation of Coverage Report on Vivos Therapeutics, Inc., "New Strategic Model & Key Regulatory Milestones Provide Revenue Tailwind" - Big News Network
Vivos, Cellev8 Launch Strategic Sleep Apnea Venture: FDA-Cleared Devices Meet Breakthrough Nutraceuticals - StockTitan
Groundbreaking Collaboration: Vivos Therapeutics and Cellev8 Nutrition Join Forces to Address Sleep Apnea and Oxidative Stress - ACCESS Newswire
Vivos and SleepImage © Revolutionize Sleep Apnea Diagnostics with Affordable Home Sleep Testing Solutions - PR Web
Vivos Therapeutics shareholders elect directors, approve equity plan By Investing.com - Investing.com South Africa
Vivos Therapeutics shareholders elect directors, approve equity plan - Investing.com India
Sleep Apnea: Vivos' FDA-Cleared Technology Offers Revolutionary, Non-Invasive Hope for America's Stealth Epidemic - PR Web
Medicare to reimburse for Vivos CARE sleep apnea devices - MSN
Ascendiant Capital Markets Reiterates Buy Rating for Vivos Therapeutics (NASDAQ:VVOS) - Defense World
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Earnings call: Vivos Therapeutics sees revenue growth in Q3 2024 - Investing.com
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2024 Earnings Call Transcript - Insider Monkey
ARMISTICE CAPITAL, LLC Acquires New Stake in Vivos Therapeutics Inc - GuruFocus.com
Vivos Therapeutics Inc (VVOS) Quarterly 10-Q Report - Quartzy
Q3 Brings Revenue Gains and Key Regulatory Milestones for Vivos - Sleep Review
Vivos Therapeutics Reports Revenue Growth and Strategic Milestones - TipRanks
Vivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3 - Proactive Investors USA
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update - The Manila Times
Vivos Therapeutics Q3 Revenue Jumps 17% as FDA Approves Pediatric OSA Treatment | VVOS Stock News - StockTitan
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call - The Manila Times
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely - Simply Wall St
Finanzdaten der Vivos Therapeutics Inc-Aktie (VVOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.16%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):